Skip to main content

Advertisement

Log in

Contribution of subjective Disease Activity Score 28 (DAS28) components to the response to treatment of rheumatoid arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

We investigated the contributions made by the subjective components of the Disease Activity Score 28 (DAS28) to the treatment response of rheumatoid arthritis (RA). In addition, factors associated with poor response to treatment at 6 months, despite normalization of objective measures, were examined. A total of 426 newly diagnosed RA patients were included. The DAS28-P score (the subjective components of the DAS28 relative to the total components) was calculated as DAS28-P = 0.56 ∗ sqrt(TJC28) + 0.014 ∗ (VAS-GH) /0.56 ∗ sqrt(TJC28) + 0.28 ∗ sqrt(SJC28) + 0.7 ∗ In(erythrocyte sedimentation rate (ESR)) + 0.014 ∗ (VAS-GH). The European League Against Rheumatism (EULAR) response was assessed after 6 months of treatment. Of those who failed to attain good EULAR responses, those for whom the objective measures (the ESR, the C-reactive protein level, and swollen joints) were normalized were defined as having failed treatment because of subjective measures. The median (IQR) DAS28 score at baseline was 4.8 (4.04–5.49) and that after 6 months of treatment 3.21 (2.41–3.95). The DAS28-P score fell significantly from baseline to 6 months in good (0.43 versus 0.28, p < 0.001) and moderate responders (0.44 versus 0.4, p = 0.003), but not in non-responders (0.43 versus 0.45, p = 0.727). Younger age, a lower DAS28 score, and a lower DAS28-P score at baseline were related to a good EULAR response. Subjects who failed to respond because of subjective measures tended to have higher DAS28-P scores at baseline. We found that RA patients with high DAS28-P scores, reflecting subjective measures, were less likely to achieve good EULAR responses 6 months after treatment initiation and tended not to be classified as good responders despite normalization of objective measures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Storage SS, Agrawal H, Furst DE (2010) Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med 25:1–17

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Jurgens MS, Overman CL, Jacobs JW, Geenen R, Cuppen BV, Marijnissen AC et al (2015) Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis. Arthritis Care Res (Hoboken) 67:923–928

    Article  Google Scholar 

  3. McWilliams DF, Zhang W, Mansell JS, Kiely PD, Young A, Walsh DA (2012) Predictors of change in bodily pain in early rheumatoid arthritis: an inception cohort study. Arthritis Care Res (Hoboken) 64:1505–1513

    Article  Google Scholar 

  4. Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R (2015) Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis 74:890–896

    Article  CAS  PubMed  Google Scholar 

  5. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48

    Article  CAS  PubMed  Google Scholar 

  6. Fransen J, van Riel PL (2005) The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23:S93–S99

    CAS  PubMed  Google Scholar 

  7. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J et al (2009) Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68:954–960

    Article  CAS  PubMed  Google Scholar 

  8. Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA et al (2011) Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 13:R83

    Article  PubMed  PubMed Central  Google Scholar 

  9. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B (2007) Disease activity score-28 values differ considerably depending on patient’s pain perception and sex. J Rheumatol 34:2382–2387

    CAS  PubMed  Google Scholar 

  10. Andersson ML, Svensson B, Bergman S (2013) Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years. J Rheumatol 40:1977–1985

    Article  PubMed  Google Scholar 

  11. Joharatnam N, McWilliams DF, Wilson D, Wheeler M, Pande I, Walsh DA (2015) A cross sectional study of pain sensitivity, disease activity assessment, mental health and fibromyalgia status in rheumatoid arthritis. Arthritis Res Ther 17:11

    Article  PubMed  PubMed Central  Google Scholar 

  12. Campbell RC, Batley M, Hammond A, Ibrahim F, Kingsley G, Scott DL (2012) The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Clin Rheumatol 31:717–722

    Article  PubMed  Google Scholar 

  13. Cordingley L, Prajapati R, Plant D, Maskell D, Morgan C, Ali FR et al (2014) Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:861–868

    Article  Google Scholar 

  14. Ranzolin A, Brenol JC, Bredemeier M, Guarienti J, Rizzatti M, Feldman D et al (2009) Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 61:794–800

    Article  PubMed  Google Scholar 

  15. Walsh DA, McWilliams DF (2014) Mechanisms, impact and management of pain in rheumatoid arthritis. Nat Rev Rheumatol 10:581–592

    Article  CAS  PubMed  Google Scholar 

  16. Altawil R, Saevarsdottir S, Wedren S, Alfredsson L, Klareskog L, Lampa J (2016) Remaining pain is common in early rheumatoid arthritis patients treated with methotrexate. Arthritis Care Res (Hoboken) 68(8):1061–1068

    Article  CAS  Google Scholar 

  17. Nieto FR, Clark AK, Grist J, Hathway GJ, Chapman V, Malcangio M (2016) Neuron-immune mechanisms contribute to pain in early stages of arthritis. J Neuroinflammation 13:96

    Article  PubMed  PubMed Central  Google Scholar 

  18. Agalave NM, Larsson M, Abdelmoaty S, Su J, Baharpoor A, Lundback P et al (2014) Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates pain-like behavior in experimental arthritis. Pain 155:1802–1813

    Article  CAS  PubMed  Google Scholar 

  19. Bas DB, Su J, Sandor K, Agalave NM, Lundberg J, Codeluppi S et al (2012) Collagen antibody-induced arthritis evokes persistent pain with spinal glial involvement and transient prostaglandin dependency. Arthritis Rheum 64:3886–3896

    Article  CAS  PubMed  Google Scholar 

  20. Christensen AW, Rifbjerg-Madsen S, Christensen R, Dreyer L, Tillingsoe H, Seven S et al (2016) Non-nociceptive pain in rheumatoid arthritis is frequent and affects disease activity estimation: cross-sectional data from the FRAME study. Scand J Rheumatol 45(6):461–469

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hyun Ah Kim.

Ethics declarations

Disclosures

None.

Ethics approval and consent to participate

The study and use of patient data were approved by the Ethics Committee of the Hallym University Medical Center (approval number 2012-I001). This was a retrospective study using data obtained from routine practice, and our IRB waive patient consent for this type of study. Thus, patient consent was not obtained.

Consent for publication

Not applicable.

Funding

This work was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C2248, HI15C2699).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Son, K.M., Lee, S.Y., Seo, Y.I. et al. Contribution of subjective Disease Activity Score 28 (DAS28) components to the response to treatment of rheumatoid arthritis. Clin Rheumatol 36, 1221–1227 (2017). https://doi.org/10.1007/s10067-017-3628-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3628-3

Keywords

Navigation